Regulation of the endothelial plasminogen activator system by fluvastatin: Role of Rho family proteins, actin polymerisation and p38 MAP kinase

Thrombosis and Haemostasis

Volumn 105, Issue 3, 2011, Pages 461-472

  Dunoyer Geindre, Sylvie ^a   Fish, Richard J ^a,b   Kruithof, Egbert K O ^a  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^b UNIVERSITY OF GENEVA MEDICAL SCHOOL   (Switzerland)

Author keywords

Actin polymerization; Endothelial cells; p38; PAI 1; Rho family proteins; Statin; t PA

Indexed keywords

ADENOVIRUS VECTOR; FLUINDOSTATIN; GERANYLGERANYL TRANSFERASE; GUANINE NUCLEOTIDE BINDING PROTEIN; LATRUNCULIN B; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE P38; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTEIN CDC42; PROTEIN P38ALPHA; PROTEIN P38BETA; RAC1 PROTEIN; RHO FACTOR; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN; SMALL INTERFERING RNA; STRESS ACTIVATED PROTEIN KINASE; SYNAPTOPHYSIN; TISSUE PLASMINOGEN ACTIVATOR; TRANSFERASE; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; ENDOTHELIUM CELL; ENZYME INHIBITION; HUMAN; HUMAN CELL; PLASMINOGEN ACTIVATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; UMBILICAL VEIN;

ACTINS; ADENOVIRIDAE; ALKYL AND ARYL TRANSFERASES; BICYCLO COMPOUNDS, HETEROCYCLIC; CDC42 GTP-BINDING PROTEIN; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIAL CELLS; FATTY ACIDS, MONOUNSATURATED; GTP-BINDING PROTEINS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INDOLES; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PLASMINOGEN ACTIVATORS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, SMALL INTERFERING; THIAZOLIDINES;

EID: 79952527104     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH10-07-0444     Document Type: Article

References (28)

1. Takemoto M, Liao JK. Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors. Arterioscler Thromb Vasc Biol 2001; 21: 1712-1719. (Pubitemid 34219772)
2. Essig M, Nguyen G, Prié D, et al. 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors increase fibrinolytic activity in rat aortic endothelial cells. Role of geranylgeranylation and Rho proteins. Circ Res 1998; 83: 683-690. (Pubitemid 28462781)
3. Mussoni L, Banfi C, Sironi L, et al. Fluvastatin inhibits basal and stimulated plasminogen activator inhibitor 1, but induces tissue type plasminogen activator in cultured human endothelial cells. Thromb Haemost 2000; 84: 59-64. (Pubitemid 30433669)
4. Bourcier T, Libby P. HMG CoA reductase inhibitors reduce plasminogen activator inhibitor-1 expression by human vascular smooth muscle and endothelial cells. Arterioscler Thromb Vasc Biol 2000; 20: 556-562. (Pubitemid 30086117)
5. Wiesbauer F, Kaun C, Zorn G, et al. HMG CoA reductase inhibitors affect the fibrinolytic system of human vascular cells in vitro: a comparative study using different statins. Br J Pharmacol 2002; 135: 284-292. (Pubitemid 34102123)
6. Vojtek AB, Cooper JA. Rho family members, activators of MAP kinase cascades. Cell 1995; 82: 527-529.
7. Dunoyer-Geindre S, Kruithof EK, Galve-de Rochemonteix B, et al. Localization of beta2-glycoprotein 1 in late endosomes of human endothelial cells. Thromb Haemost 2001; 85: 903-907. (Pubitemid 32421826)
8. Fish RJ, Kruithof EK. Short-term cytotoxic effects and long-term instability of RNAi delivered using lentiviral vectors. BMC Mol Biol 2004; 5: 9.
9. Huber D, Cramer EM, Kaufmann JE, et al. Tissue-type plasminogen activator (t-PA) is stored in Weibel-Palade bodies in human endothelial cells both in vitro and in vivo. Blood 2002; 99: 3637-3645. (Pubitemid 34534533)
10. Fish RJ, Yang H, Viglino C, et al. Fluvastatin inhibits regulated secretion of endothelial cell von Willebrand factor in response to diverse secretagogues. Biochem J 2007; 405: 597-604. (Pubitemid 47172058)
11. Siekmeier R, Lattke P, Mix C, et al. Dose dependency of fluvastatin pharmacokinetics in serum determined by reversed phase HPLC. J Cardiovasc Pharmacol Ther 2001; 6: 137-145. (Pubitemid 32977709)
12. Lobell RB, Omer CA, Abrams MT, et al. Evaluation of farnesyl:protein transferase and geranylgeranyl:protein transferase inhibitor combinations in preclinical models. Cancer Res. 2001; 61: 8758-8768. (Pubitemid 34013888)
13. Turner SJ, Zhuang S, Zhang T, et al. Effects of lovastatin on Rho isoform expression, activity, and association with guanine nucleotide dissociation inhibitors. Biochem Pharmacol. 2008; 7: 405-413. (Pubitemid 350298465)
14. Heasman SJ, Ridley AJ. Mammalian Rho GTPases: new insights into their functions from in vivo studies. Nat Rev Mol Cell Biol 2008; 9: 690-701.
15. Bain J, Plater L, Elliott M, et al. The selectivity of protein kinase inhibitors: a further update. Biochem J 2007; 408: 297-315.
16. Ho TT, Merajver SD, Lapière CM, et al. RhoA-GDP regulates RhoB protein stability. Potential involvement of RhoGDIalpha. J Biol Chem. 2008; 283: 21588-21598.
17. Takeda K, Ichiki T, Tokunou T, et al. Critical role of Rho-kinase and MEK/ERK pathways for angiotensin II-induced plasminogen activator inhibitor type-1 gene expression. Arterioscler Thromb Vasc Biol 2001; 21: 868-873. (Pubitemid 32448782)
18. Kunieda Y, Nakagawa K, Nishimura H, et al. HMG CoA reductase inhibitor suppresses the expression of tissue factor and plasminogen activator inhibitor-1 induced by angiotensin II in cultured rat aortic endothelial cells. Thromb Res 2003; 110: 227-234.
19. Rikitake Y, Liao JK. Rho-kinase mediates hyperglycemia-induced plasminogen activator inhibitor-1 expression in vascular endothelial cells. Circulation 2005; 111: 3261-3268. (Pubitemid 40874999)
20. Kato T, Hashikabe H, Iwata C, et al. Statin blocks Rho/Rho-kinase signalling and disrupts the actin cytoskeleton: relationship to enhancement of LPS-mediated nitric oxide synthesis in vascular smooth muscle cells. Biochim Biophys Acta 2004; 1689: 267-272. (Pubitemid 38981604)
21. Yang C, Patel K, Harding P, et al. Regulation of TGF-beta1/MAPK-mediated PAI-1 gene expression by the actin cytoskeleton in human mesangial cells. Exp Cell Res. 2007; 313: 1240-1250. (Pubitemid 46427822)
22. Frigeri L, Apgar JR. The role of actin microfilaments in the down-regulation of the degranulation response in RBL-2H3 mast cells. J Immunol. 1999; 16: 2243-2250. (Pubitemid 29288847)
23. Providence KM, Kutz SM, Higgins PJ. Perturbation of the actin cytoskeleton induces PAI-1 gene expression in cultured epithelial cells independant of substrate anchorage. Cell Motil Cytoskeleton. 1999; 42: 218-229. (Pubitemid 29142951)
24. Samarakoon R, Higgins PJ. MEK/ERK pathway mediates cell-shape-dependent plasminogen activator inhibitor type 1 gene expression upon drug-induced disruption of the microfilament and microtubule networks. J Cell Sci. 2002; 115: 3093-3103.
25. Kusterman G, Piette J, Legrand-Poels S. Actin-targeting natural compounds as tool to study the role of actin cytoskeleton in signal transduction. Biochem Pharmacol 2008; 76: 1310-1322.
26. Ulfhammer E, Larsson P, Karlsson L, et al. TNF-alpha mediated suppression of tissue type plasminogen activator expression in vascular endothelial cells is NF-kappaB-and p38 MAPK-dependent. J Thromb Haemost 2006; 4: 1781-1789. (Pubitemid 44144806)
27. Nakajima K, Suga H, Matsuno H, et al. Differential roles of MAP kinases in atorvastatin-induced VEGF release in cardiac myocytes. Life Sci 2006; 79: 1214-1220. (Pubitemid 44128585)
28. Pepper MS, Rosnoblet C, Di Sanza C, et al. Synergistic induction of t-PA by vascular endothelial growth factor and basic fibroblast growth factor and localization of t-PA to Weibel-Palade bodies in bovine microvascular endothelial cells. Thromb Haemost 2001; 86: 702-709. (Pubitemid 32743288)